Celecoxib Has Potent Antitumour Effects As A Single Agent And In Combination With BCG Immunotherapy In A Model Of Urothelial Cell Carcinoma
The authors evaluated the role of Celecoxib, an inhibitor of Prostaglandin E(2) (PGE(2)), which is a potent immune modulator in the treatment of urothelial cancer. PGE(2) is known to suppress both tumour antigen-specific helper T (T(H)1) cells and the generation of cytotoxic T lymphocytes (CTLs).